keyword
https://read.qxmd.com/read/31490382/effectiveness-of-the-traditional-japanese-kampo-medicine-yokukansan-for-chronic-migraine-a-case-report
#21
JOURNAL ARTICLE
Hisanao Akiyama, Yasuhiro Hasegawa
RATIONALE: The traditional Japanese Kampo medicine Yokukansan (TSUMURA Yokukansan extract granules) was originally used to treat neurosis, insomnia, night crying, and irritability and/or agitation in infants and recently it has also been used for neuropsychiatric symptoms in Alzheimer's disease or other dementia in Japan. Furthermore, several recent studies have reported the efficacy of Kampo medicines for various types of headache. Here, we report a case of severe chronic migraine refractory to prophylactic therapy using various western medicines and Japanese Kampo medicines that had resulted in a leave of absence from work, but for which the frequency and severity were markedly decreased by Yokukansan (2...
September 2019: Medicine (Baltimore)
https://read.qxmd.com/read/30893319/beta-blockers-for-the-prevention-of-headache-in-adults-a-systematic-review-and-meta-analysis
#22
JOURNAL ARTICLE
Jeffrey L Jackson, Akira Kuriyama, Yachiyo Kuwatsuka, Sarah Nickoloff, Derek Storch, Wilkins Jackson, Zhi-Jiang Zhang, Yasuaki Hayashino
BACKGROUND: Headaches are a common source of pain and suffering. The study's purpose was to assess beta-blockers efficacy in preventing migraine and tension-type headache. METHODS: Cochrane Register of Controlled Trials; MEDLINE; EMBASE; ISI Web of Science, clinical trial registries, CNKI, Wanfang and CQVIP were searched through 21 August 2018, for randomized trials in which at least one comparison was a beta-blocker for the prevention of migraine or tension-type headache in adults...
2019: PloS One
https://read.qxmd.com/read/30600979/migraine-headache-prophylaxis
#23
JOURNAL ARTICLE
Hien Ha, Annika Gonzalez
Migraines impose significant health and financial burdens. Approximately 38% of patients with episodic migraines would benefit from preventive therapy, but less than 13% take prophylactic medications. Preventive medication therapy reduces migraine frequency, severity, and headache-related distress. Preventive therapy may also improve quality of life and prevent the progression to chronic migraines. Some indications for preventive therapy include four or more headaches a month, eight or more headache days a month, debilitating headaches, and medication-overuse headaches...
January 1, 2019: American Family Physician
https://read.qxmd.com/read/30231626/benefit-risk-assessment-of-erenumab-and-current-migraine-prophylactic-treatments-using-the-likelihood-of-being-helped-or-harmed
#24
JOURNAL ARTICLE
Pamela Vo, Shihua Wen, Marie-Josée Martel, Dimos Mitsikostas, Uwe Reuter, Jan Klatt
OBJECTIVE: This study evaluated the benefit-risk profile of erenumab relative to other therapies approved for migraine prophylaxis and available in the majority of European countries. METHODS: Trials were identified via a published systematic literature review updated to December 2017 using MEDLINE. Erenumab's pivotal trials study reports were also included (NCT02066415, NCT02456740). From these sources, ≥ 50% responder rates and discontinuations due to adverse events were extracted to generate numbers needed to treat and harm and likelihood of being helped or harmed, a quantitative benefit-risk measure...
April 2019: Cephalalgia: An International Journal of Headache
https://read.qxmd.com/read/30137671/pharmacologic-prevention-of-migraine-a-narrative-review-of-the-state-of-the-art-in-2018
#25
REVIEW
Elizabeth Loder, Paul Rizzoli
This paper describes current non-antibody pharmacologic approaches to the prevention of migraine in adults. Preventive therapy should be considered for patients with migraine who routinely have more than 6 headache days per month or in other special circumstances. Choices for preventive therapy are based on patient preferences about side effects and evidence of efficacy. The evidence level and commonly used doses for selected categories of migraine preventive medication are reviewed, including antiepileptic drugs, antihypertensive drugs, and antidepressants...
November 2018: Headache
https://read.qxmd.com/read/29512871/flunarizine-in-migraine-related-headache-prevention-results-from-200-patients-treated-in-the-uk
#26
JOURNAL ARTICLE
N Karsan, D Palethorpe, W Rattanawong, J C Marin, R Bhola, P J Goadsby
BACKGROUND AND PURPOSE: For over 20 years, as a group we have been using flunarizine in primary headache disorders. Flunarizine is widely used in Europe, but not licensed in the UK. In September 2014, the National Institute for Clinical Excellence published supportive guidelines for flunarizine use in migraine, based on randomized controlled evidence that it is as effective as propranolol and topiramate in adults. METHODS: We reviewed a cohort of adult patients (n = 200) treated with flunarizine from our practice...
June 2018: European Journal of Neurology
https://read.qxmd.com/read/29022756/soluble-guanylyl-cyclase-is-a-critical-regulator-of-migraine-associated-pain
#27
JOURNAL ARTICLE
Manel Ben Aissa, Alycia F Tipton, Zachariah Bertels, Ronak Gandhi, Laura S Moye, Madeline Novack, Brian M Bennett, Yueting Wang, Vladislav Litosh, Sue H Lee, Irina N Gaisina, Gregory Rj Thatcher, Amynah A Pradhan
Background Nitric oxide (NO) has been heavily implicated in migraine. Nitroglycerin is a prototypic NO-donor, and triggers migraine in humans. However, nitroglycerin also induces oxidative/nitrosative stress and is a source of peroxynitrite - factors previously linked with migraine etiology. Soluble guanylyl cyclase (sGC) is the high affinity NO receptor in the body, and the aim of this study was to identify the precise role of sGC in acute and chronic migraine. Methods We developed a novel brain-bioavailable sGC stimulator (VL-102), and tested its hyperalgesic properties in mice...
July 2018: Cephalalgia: An International Journal of Headache
https://read.qxmd.com/read/28965306/current-treatment-options-vestibular-migraine
#28
REVIEW
Clinton G Lauritsen, Michael J Marmura
Vestibular migraine (VM) is a disorder with a spectrum of clinical presentations and among the most common causes of chronic vestibular symptoms. Some present with attacks before or during typical migraine, but many others have fluctuating or daily symptoms. While the symptoms and pathogenesis of vestibular migraine may have elements of both central and peripheral disorders, hearing loss should be absent. VM typically worsens with activity and head movements in general, and encompasses symptoms of vertigo, disequilibrium, or imbalance...
September 30, 2017: Current Treatment Options in Neurology
https://read.qxmd.com/read/28800342/use-of-melatonin-versus-valproic-acid-in-prophylaxis-of-migraine-patients-a-double-blind-randomized-clinical-trial
#29
RANDOMIZED CONTROLLED TRIAL
Mohsen Ebrahimi-Monfared, Mojtaba Sharafkhah, Ali Abdolrazaghnejad, Abolfazl Mohammadbeigi, Fardin Faraji
BACKGROUND: Melatonin is known to be effective in curing migraine. OBJECTIVE: This study aimed to investigate the therapeutic effect of melatonin versus sodium valproate in the prophylaxis of chronic migraine. METHODS: This randomized, double-blind, placebo-controlled clinical trial included patients with chronic migraine who were divided into three equal sized groups, and baseline therapy with nortriptyline (10-25 mg) and propranolol (20-40 mg) was used...
2017: Restorative Neurology and Neuroscience
https://read.qxmd.com/read/28752512/medical-treatment-guidelines-for-preventive-treatment-of-migraine
#30
JOURNAL ARTICLE
Tzu-Chou Huang, Tzu-Hsien Lai, Treatment Guideline Subcommittee Of Taiwan Headache Society Taiwan Headache Society
The Treatment Guideline Subcommittee of the Taiwan Headache Society evaluated the medications currently used for migraine prevention in Taiwan. We assessed the results of new published drug trials, information from medical database and referred to the latest guidelines published. After comprehensive discussion, we proposed Taiwanese consensus about the preventive treatment for migraine including recommendation levels, strength of evidences, and related prescription information regarding dosage and adverse effects...
March 15, 2017: Acta Neurologica Taiwanica
https://read.qxmd.com/read/28700539/propranolol-treatment-prevents-chronic-central-sensitization-induced-by-repeated-dural-stimulation
#31
JOURNAL ARTICLE
Nelly Boyer, Jérémy Signoret-Genest, Alain Artola, Radhouane Dallel, Lénaïc Monconduit
Migraine is currently conceptualized as a chronic disease with episodic manifestations. In some patients, migraine attack frequency increases, leading to chronic migraine. Daily preventive therapy is initiated to decrease attack frequency. Propranolol, a first-line medication for migraine prophylaxis, reduces attack frequency in nearly 50% of patients receiving it. However, the mechanisms of its antimigraine action are unclear. We examined the effect of daily propranolol treatment (10 mg·kg per os, 8 days) in a rat model of recurrent activation of dural nociceptors (repeated infusion of an inflammatory soup (IS) on the dura through a cannula every 2-3 days)...
October 2017: Pain
https://read.qxmd.com/read/28565942/recurrent-administration-of-the-nitric-oxide-donor-isosorbide-dinitrate-induces-a-persistent-cephalic-cutaneous-hypersensitivity-a-model-for-migraine-progression
#32
JOURNAL ARTICLE
Radhouane Dallel, Amélie Descheemaeker, Philippe Luccarini
Background A subgroup of migraineurs experience an increase in attack frequency leading to chronic migraine. Methods We assessed in rats the roles of dose and repeat administration of systemic isosorbide dinitrate (ISDN), a nitric oxide donor, on the occurrence and development of cephalic/face and extracephalic/hindpaw mechanical allodynia as a surrogate of migraine pain, and the effect of acute systemic sumatriptan and olcegepant and chronic systemic propranolol on these behavioral changes. Results A single high (H-ISDN) but not low (L-ISDN) dose of ISDN induces a reversible cephalic and extracephalic mechanical allodynia...
April 2018: Cephalalgia: An International Journal of Headache
https://read.qxmd.com/read/28220376/unveiling-the-relative-efficacy-safety-and-tolerability-of-prophylactic-medications-for-migraine-pairwise-and-network-meta-analysis
#33
JOURNAL ARTICLE
Aijie He, Dehua Song, Lei Zhang, Chen Li
BACKGROUND: A large number patients struggle with migraine which is classified as a chronic disorder. The relative efficacy, safety and tolerability of prophylactic medications for migraine play a key role in managing this disease. METHODS: We conducted an extensive literature search for popular prophylactic medications that are used for migraine patients. Pairwise meta-analysis and network meta-analysis (NMA) were carried out sequentially for determining the relative efficacy, safety and tolerability of prophylactic medications...
December 2017: Journal of Headache and Pain
https://read.qxmd.com/read/27902848/topiramate-in-migraine-prevention-a-2016-perspective
#34
REVIEW
Stephen D Silberstein
BACKGROUND: In evidence-based guidelines published in 2000, topiramate was a third-tier migraine preventive with no scientific evidence of efficacy; recommendation for its use reflected consensus opinion and clinical experience. Its neurostabilizing activity, coupled with its favorable weight profile, made topiramate an attractive alternative to other migraine preventives that caused weight gain. When guidelines for migraine prevention in episodic migraine were published in 2012, topiramate was included as a first-line option based on double-blind, randomized controlled trials involving nearly 3000 patients...
January 2017: Headache
https://read.qxmd.com/read/26682574/the-effects-of-acute-and-preventive-migraine-therapies-in-a-mouse-model-of-chronic-migraine
#35
JOURNAL ARTICLE
Alycia F Tipton, Igal Tarash, Brenna McGuire, Andrew Charles, Amynah A Pradhan
Background The development of novel migraine therapies has been slow, in part because of the small number of clinically relevant animal models. We have recently developed a new mouse model of chronic migraine using chronic intermittent nitroglycerin, a known human migraine trigger. The objective of this study was to validate this model by testing known and potential migraine-preventive treatments. Methods Migraine therapies were administered to male and female mice for 11 days. On day 3, mice were tested with nitroglycerin every second day for nine days...
October 2016: Cephalalgia: An International Journal of Headache
https://read.qxmd.com/read/25869942/cost-effectiveness-analysis-of-interventions-for-migraine-in-four-low-and-middle-income-countries
#36
JOURNAL ARTICLE
Mattias Linde, Timothy J Steiner, Dan Chisholm
BACKGROUND: Evidence of the cost and effects of interventions for reducing the global burden of migraine remains scarce. Our objective was to estimate the population-level cost-effectiveness of evidence-based migraine interventions and their contributions towards reducing current burden in low- and middle-income countries. METHODS: Using a standard WHO approach to cost-effectiveness analysis (CHOICE), we modelled core set intervention strategies for migraine, taking account of coverage and efficacy as well as non-adherence...
February 18, 2015: Journal of Headache and Pain
https://read.qxmd.com/read/25567755/trends-in-the-ambulatory-management-of-headache-analysis-of-namcs-and-nhamcs-data-1999-2010
#37
COMPARATIVE STUDY
John N Mafi, Samuel T Edwards, Nigel P Pedersen, Roger B Davis, Ellen P McCarthy, Bruce E Landon
BACKGROUND: Headache is a frequent complaint and among the most common reasons for visiting a physician. OBJECTIVE: To characterize trends from 1999 through 2010 in the management of headache. DESIGN: Longitudinal trends analysis. DATA: Nationally representative sample of visits to clinicians for headache from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, excluding visits with "red flags," such as neurologic deficit, cancer, or trauma...
May 2015: Journal of General Internal Medicine
https://read.qxmd.com/read/24784123/chronic-daily-headache-diagnosis-and-management
#38
JOURNAL ARTICLE
Joseph R Yancey, Richard Sheridan, Kelly G Koren
Chronic daily headache is defined as the presence of a headache on 15 days or more per month for at least three months. The most common types of chronic daily headache are chronic migraines and chronic tension-type headaches. If a red flag for a secondary cause of headache is present, magnetic resonance imaging of the head should be performed. All patients should be asked about medication overuse, which can increase the frequency of headaches. Patients who overuse medications for abortive therapy for headache should be encouraged to stop the medications entirely and consider prophylactic treatment...
April 15, 2014: American Family Physician
https://read.qxmd.com/read/24372457/systematic-review-of-migraine-prophylaxis-adherence-and-persistence
#39
REVIEW
Zsolt Hepp, Lisa M Bloudek, Sepideh F Varon
BACKGROUND: Migraine is a common neurological disease affecting 12% of Americans and millions worldwide. Medication adherence has been studied extensively in many chronic conditions, with poor adherence adversely affecting treatment outcomes. However, little is known about adherence to oral prophylaxis for migraine. OBJECTIVE: To examine the literature on assessing oral prophylaxis medication adherence and persistence among migraine patients. METHODS: A systematic search of the PubMed (1966 to present) and EMBASE (1974 to present) databases was conducted to locate prospective and retrospective observational studies and randomized controlled trials (RCTs) of propranolol, amitriptyline, and topiramate...
January 2014: Journal of Managed Care Pharmacy: JMCP
https://read.qxmd.com/read/24335848/a-comparative-study-of-candesartan-versus-propranolol-for-migraine-prophylaxis-a-randomised-triple-blind-placebo-controlled-double-cross-over-study
#40
RANDOMIZED CONTROLLED TRIAL
Lars J Stovner, Mattias Linde, Gøril B Gravdahl, Erling Tronvik, Anne H Aamodt, Trond Sand, Knut Hagen
OBJECTIVE: The objective of this article is to see whether the effect of candesartan for migraine prevention, shown in one previous study, could be confirmed in a new study, and if so, whether the effect was comparable to that of propranolol (non-inferiority analysis), and whether adverse events were different. METHODS: In a randomised, triple-blind, double cross-over study, 72 adult patients with episodic or chronic migraine went through three 12-week treatment periods on either candesartan 16 mg, propranolol slow-release 160 mg, or placebo...
June 2014: Cephalalgia: An International Journal of Headache
keyword
keyword
67527
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.